Targets › GDAP1
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Dec 2028.
Regulates the mitochondrial network by promoting mitochondrial fission. (UniProt, Q8TB36)
Open in Phaseline: the race on GDAP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Xuanwu Hospital, Beijing | Efavirenz Human immunodeficiency virus type 1 reverse transcriptase inhibitor | GDAP1, NSCL1 | Phase 3 | Creutzfeldt-Jakob Disease | Dec 2028 |
Creutzfeldt-Jakob Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.